Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD9150 + durvalumab + gemcitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**AZD9150 + durvalumab + gemcitabine + cisplatin** is an investigational four-drug combination regimen under clinical evaluation primarily for advanced solid tumors, including biliary tract cancer. AZD9150 is an antisense oligonucleotide targeting STAT3 to downregulate its expression and inhibit tumor-promoting pathways. Durvalumab (code name MEDI4736) is a monoclonal antibody that blocks PD-L1, releasing inhibition of anti-tumor immune activity. Gemcitabine and cisplatin are standard chemotherapeutic agents: gemcitabine is a nucleoside analog inhibiting DNA synthesis, and cisplatin is a platinum-based DNA crosslinker causing apoptosis in rapidly dividing cells. The combination aims to synergistically suppress tumor growth through complementary immunotherapy, targeted therapy, and cytotoxic effects[1].
- Other names
- AZD9150 + MEDI4736 + gemcitabine + cisplatin
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on AZD9150 + durvalumab + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD9150 + durvalumab + gemcitabine + cisplatin.